Alzinova AB
78D
Company Profile
Business description
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is engaged in the development of a specific oligomer-directed vaccine (ALZ-101), and ALZ-201 which is a monoclonal antibody that is specific for the toxic AB oligomers. The products of the company are in the clinical and preclinical stages of development as a therapeutic vaccine for the treatment of Alzheimer’s.
Contact
Entreprenorsstraket 10
Molndal431 53
SWESector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Wide moat miner looking to shift focus
Investors cheered an increased dividend but still heavily dependent on iron ore.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,227.50 | 10.30 | 0.11% |
| CAC 40 | 8,361.46 | 44.96 | 0.54% |
| DAX 40 | 24,998.40 | 197.49 | 0.80% |
| Dow JONES (US) | 49,533.19 | 32.26 | 0.07% |
| FTSE 100 | 10,545.22 | 71.53 | 0.68% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,578.38 | 31.71 | 0.14% |
| Nikkei 225 | 57,258.72 | 692.23 | 1.22% |
| NZX 50 Index | 13,247.02 | 215.40 | 1.65% |
| S&P 500 | 6,843.22 | 7.05 | 0.10% |
| S&P/ASX 200 | 8,998.20 | 4.00 | 0.04% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |